Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.

  title={Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.},
  author={Tarik Asselah and Patrick Marcellin},
  journal={Liver international : official journal of the International Association for the Study of the Liver},
  volume={34 Suppl 1},
With the approval of second-wave direct-acting antivirals simeprevir, sofosbuvir and faldaprevir in 2014-2015, for genotype 1 hepatitis C, patients and doctors will have more treatment options. During a first period, these treatments will still be used with peginterferon and ribavirin. The second wave of IFN-based triple therapy will have benefits and risk. These treatments have the following advantages: higher efficacy with more patient candidates for a shorten treatment duration (12-24 weeks… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 31 extracted citations


Publications referenced by this paper.
Showing 1-10 of 22 references

STARTVerso 4 phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response

  • JK Rockstroh, M Nelson, V Soriano
  • 2013
Highly Influential
8 Excerpts


  • IM Jacobson, RH Ghalib, M Rodriguez-Torres, 1 treatment-na€ıveetal.Simeprevirplussofosbuvirwitho, patients prior null responder
  • Hepatology 2013, AASLD; LB3. Liver International
  • 2014
1 Excerpt

results Table 5

  • I Jacobson, GJ Dore, GR Foster, patients et al. Simeprevir with peginterferonribavirin for treatment-nave
  • Perspectives for HCV treatment Liver…
  • 2014
2 Excerpts

Faldaprevir combined with peginterferon alfa-2a and ribivirin in treatment-na€ıve patients with chronic genotype 1 HCV: SILEN-C1 trial

  • MS Sulkowski, T Asselah, J Lalezari
  • Hepatology
  • 2013
2 Excerpts

High sustained viral response of MK-5172 with pegylated interferon alfa2b and ribavirin in HCV genotype-1 treatment naive noncirrhotic patient (EASL)

  • M Manns, JM Vierling, BR Bacon
  • J Hepatol,
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…